

Fenofibrate for Compensated Cirrhosis Patients With Primary Biliary Cholangitis

NCT05749822

Status	RECRUITING
Phase	Phase 2, Phase 3
Sponsor	Xijing Hospital of Digestive Diseases
Enrollment	104 participants

Key Eligibility Criteria

Inclusion (14)

- Must have provided written informed consent
- Age 18-75 years;
- BMI 17-28 kg/m²
- Male or female with a diagnosis of PBC, by at least two of the following criteria:
- History of AP above ULN for at least six months;
- ... and 9 more (see full listing online)

Exclusion (12)

- History or presence of other concomitant liver diseases.
- ALT or AST \gt 5xULN, TBIL \gt 3xULN.
- If female: known pregnancy, or has a positive urine pregnancy test (confirmed by a positive serum pregnancy test), or lactating.
- Allergic to fenofibrate or ursodeoxycholic acid.
- Taking hepatotoxic drugs (e.g., dapsone, erythromycin, fluconazole, ketoconazole, rifampicin) for more than 2 weeks within 6 months, and long-term hormonal users.
- ... and 7 more (see full listing online)

Locations (12 total)

Peking Union Medical College Hospital, Beijing, Beijing Municipality, China
Sun Yat-sen Memorial Hospital, Guangzhou, Guangdong, China
Henan Provincial People's Hospital, Zhengzhou, Henan, China
... and 9 more locations